Objective:To explore the clinical effects of intravenous chemotherapy combined with IPHC on patients with advanced ovarian cancer(AOC).Methods:Totally 100 patients with AOC were divided into two groups by means of different intervention meth-ods.50 patients in the control group were treated with paclitaxel+carboplatin for intravenous chemotherapy,and the other 50 patients in the observation group were combined with IPHC on the basis of the control group.The clinical efficacy,tumor markers[carcinoembryon-ic antigen(CEA),alpha-fetoprotein(AFP),basic fibroblast growth factor(bFGF),human epididymis protein 4(HE4)],immune cell indicators(CD3+T cell,CD4+T cell,CD4+/CD8+T cell ratio),adverse reactions and survival status were compared between the two groups.Results:After treatment,compared with the control group,the total clinical control rate in the observation group was higher(P＜0.05).The levels of CEA,AFP,bFGF and HE4 in the observation group were lower compared with those in the control group(P＜0.05).The levels of CD3+T cell,CD4+T cell and CD4+/CD8+T cell ratio were higher in the observation group(P＜0.05).There was no statistical significance in the incidence of adverse reactions between groups(P＞0.05).After 12 months of follow-up,the survival curve revealed no statistical difference between both groups(P＞0.05).Conclusion:IPHC combined with TC intravenous chemotherapy has certain efficacy on patients with AOC,and it can reduce the tumor markers and enhance the immune function,and it will not additionally increase adverse reactions.